MedTrace Logo

Safety and Efficacy of Raltegravir+TDF+3TC in HBV/HIV Co-infected Patients

NCT01318096 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2011-03-18

No results posted yet for this study

Summary

In this pilot study, the investigators would examine the safety and efficacy of integrase inhibitor-Raltegravir in the control of HIV/HBV co-infection.

Conditions

  • HBV Coinfection
  • HIV Infections

Interventions

DRUG

raltegravir and tenofovir and lamivudine

raltegravir 400mg BID and tenofovir 300mg qd and lamivudine 300mg gd for 48 weeks

DRUG

efavirenz+tenofovir+lamivudine

efavirenz 600mg QN +tenofovir 300mg qd +lamivudine 300mg qd for 48 weeks

Sponsors & Collaborators

  • Yunnan AIDS Care Center

    lead OTHER

Principal Investigators

  • Cheng Xi Wang, M.D. · Yunnan Provincial Hospital of Infectious Diseases/Yunnan AIDS Care Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-03-31
Primary Completion
2012-07-31
Completion
2013-09-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01318096 on ClinicalTrials.gov